|
DGAP-Ad-hoc: Drägerwerk AG & Co. KGaA / Key word(s): Preliminary Results Ad-hoc notification in accordance with Sec. 17 of the MAR Drägerwerk AG & Co. KGaA: preliminary result for the first quarter 2021. Net sales and earnings considerably above prior year. On the basis of preliminary figures, however, net sales in the first quarter of 2021 were significantly higher than the same period of the previous year. Net of currency effects, net sales rose by around 28.2 percent (nominal: 23.8 percent) to around EUR 792.1 million (Q1 2020: EUR 640.0 million). Net sales increased in the medical as well as the safety division. The gross margin was around 52.1 percent (Q1 2020: 44.2 percent). The functional expenses were 2.4 percent (net of currency effects; nominal: 0.5 percent) above the previous year's figure. The EBIT for the first quarter was around EUR 129 million (Q1 2020: EUR -0.6 million), which corresponds to an EBIT margin of around 16.3 percent (Q1 2020: - 0.1 percent). For the full year, Dräger expects a currency-adjusted decline in net sales of between - 7.0 and - 11.0 percent and an EBIT margin of between 5.0 and 8.0 percent. The business development in the first quarter was above the original expectations, so that the probability of the upper end of the forecast or even exceeding the forecast has increased. The current epidemic situation does not permit a more precise forecast at this point in time and also contains signs of a general weakening of economic development. Dräger will review the forecast again at the latest with the half-year results and refine it if necessary. Dräger will publish its full results for the first quarter on April 29, 2021. Drägerwerk AG & Co. KGaA Investor Relations: Corporate Communications: Disclaimer
14-Apr-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Drägerwerk AG & Co. KGaA |
| Moislinger Allee 53-55 | |
| 23542 Lübeck | |
| Germany | |
| Phone: | +49 (0)451 882-0 |
| Fax: | +49 (0)451 882-2080 |
| E-mail: | info@draeger.com |
| Internet: | www.draeger.com |
| ISIN: | DE0005550602, DE 000 555 063 6, DE 000 555 065 1, DE 000 555 067 7, DE 000 555 071 9 |
| WKN: | 555060, 555063 Vorzüge, 555065 Genussschein A, 555067 Genussschein K, 555071 Genussschein D |
| Indices: | TecDAX |
| Listed: | Regulated Market in Berlin, Dusseldorf, Frankfurt (Prime Standard), Hamburg, Hanover, Munich; Regulated Unofficial Market in Stuttgart, Tradegate Exchange |
| EQS News ID: | 1184910 |
| End of Announcement | DGAP News Service |
|
|
1184910 14-Apr-2021 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
